During the past decade, Hospital Pedro Hispano conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 3 clinical trials were completed, i.e. on average, 30% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 2 clinical trials were completed. i.e. 28.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hospital Pedro Hispano" #1 sponsor was "Hospital Pedro Hispano" with 3 trials, followed by "Assistance Publique - Hôpitaux de Paris" with 1 trials sponsored, "AstraZeneca" with 1 trials sponsored, "Bial - Portela C S.A." with 1 trials sponsored and "Boehringer Ingelheim" with 1 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hospital Pedro Hispano" #1 collaborator was "Boehringer Ingelheim" with 1 trials as a collaborator, "Canadian Institutes of Health Research (CIHR)" with 1 trials as a collaborator, "Diogo Melo Pinto, MD, Hospital Pedro Hispano" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator and "GORTEC (Head and Neck Oncology and Radiotherapy Group)" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "Hospital Pedro Hispano" are "Squamous Cell Carcinoma of the Head and Neck" (2 trials), "Advanced or Metastatic Non-small Cell Lung Cancer" (1 trials), "Arthritis" (1 trials), "Atherosclerosis" (1 trials) and "Bleeding After Resection of Colorectal Neoplastic Lesions" (1 trials). Many other conditions were trialed in "Hospital Pedro Hispano" in a lesser frequency.

Most popular intervention types in "Hospital Pedro Hispano" are "Drug" (11 trials), "Diagnostic Test" (2 trials), "Device" (1 trials), "Other" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Alteplase" (1 trials), "Amivantamab Intravenous" (1 trials), "Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)" (1 trials) and "Analysis of cfDNA" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hospital Pedro Hispano" are 16 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Hospital Pedro Hispano". undefined are not yet recruiting, 5 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Hospital Pedro Hispano, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Hospital Pedro Hispano, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".